Initial Impression of Case
Dr. Motzer provides his perspective on the notable aspects of this nccRCC case and how it compares to typical cases.
EP: 1.Initial Impression of Case
EP: 2.Appropriateness of Initial Therapy
EP: 3.Efficacy and safety of KEYNOTE-427
EP: 4.Efficacy and Safety and Emerging Combinations
EP: 5.Efficacy of Combination vs Single Agent Therapy
EP: 6.Managing Adverse Events
EP: 7.Risk/Benefits of Managing AEs with Combination Therapy
EP: 8.Quality of Life Preservation
EP: 9.Future Management of nccRCC
FDA Accepts BLA for Subcutaneous Nivolumab Across Various Solid Tumors
May 6th 2024The FDA is considering a subcutaneous nivolumab formulation for various solid tumors based on promising data from the phase 3 CheckMate -67T trial. A target action date has been set for February 28, 2025.
Read More
Enhancing Precision in Immunotherapy: CD8 PET-Avidity in RCC
March 1st 2024In this episode of Emerging Experts, Peter Zang, MD, highlights research on baseline CD8 lymph node avidity with 89-Zr-crefmirlimab for the treatment of patients with metastatic renal cell carcinoma and response to immunotherapy.
Listen
Tolerability Helps Decide Third-Line Treatment in Advanced RCC
April 30th 2024During a Case-Based Roundtable® Chandler H. Park, MD, led a discussion on the considerations physicians have when deciding on their treatment approach in the third line for patients with advanced renal cell carcinoma in the first article of a 2-part series.
Read More
Sustained Treatment-Free Survival in RCC Seen With Nivolumab and Ipilimumab
April 30th 2024Nivolumab monotherapy plus salvage nivolumab/ipilimumab demonstrated superior treatment-free survival rates among patients with advanced renal cell carcinoma, especially in patients with favorable risk profiles.
Read More
